Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy

British Journal of Dermatology

Volumn 163, Issue 6, 2010, Pages 1282-1290

  Coimbra, S ^a,b,c   Oliveira, H ^d   Reis, F ^e   Belo, L ^a,b   Rocha, S ^a,b   Quintanilha, A ^a,b   Figueiredo, A ^d   Teixeira, F ^e   Castro, E ^a,b   Rocha Pereira, P ^b,f   Santos Silva, A ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

cytokines; growth factors; narrowband ultraviolet B; psoralen ultraviolet A; psoriasis therapy; psoriasis vulgaris

Indexed keywords

CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 8; METHOXSALEN; PSORALEN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; TH17 CELL; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ADULT; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-8; INTERLEUKINS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSORIASIS; PUVA THERAPY; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; ULTRAVIOLET THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649639288     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09992.x     Document Type: Article

References (57)

1. Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
2. Sabat R, Philipp S, Hoflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007; 16: 779-98.
3. Ghoreschi K, Weigert C, Rocken M,. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007; 25: 574-80.
4. Blauvelt A,. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128: 1064-7.
5. Torti DC, Feldman SR,. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007; 57: 1059-68.
6. Chan Jr. Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203: 2577-87.
7. Ouyang W, Kolls JK, Zheng Y,. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-67.
8. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51.
9. Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007; 9: 461-7.
10. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36: 1309-23.
11. Hunter CA,. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5: 521-31.
12. Pietrzak AT, Zalewska A, Chodorowska G, et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta 2008; 394: 7-21.
13. Takahashi H, Tsuji H, Hashimoto Y, et al. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 2010; 35: 645-9.
14. Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009; 29: 210-14.
15. Arican O, Aral M, Sasmaz S, Ciragil P,. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005: 273-9.
16. Vähävihu K, Ala-Houhala M, Peric M, et al. Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. Br J Dermatol 2010; 163: 321-8.
17. Toebak MJ, De Rooij J, Moed H, et al. Differential suppression of dendritic cell cytokine production by anti-inflammatory drugs. Br J Dermatol 2008; 158: 225-33.
18. Kastelan D, Kastelan M, Massari LP, et al. Possible association of psoriasis and reduced bone mineral density due to increased TNF-alpha and IL-6 concentrations. Med Hypotheses 2006; 67: 1403-5.
19. Asadullah K, Docke WD, Volk HD, et al. The pathophysiological role of cytokines in psoriasis. Drugs Today (Barc) 1999; 35: 913-24.
20. Narbutt J, Lesiak A, Skibinska M, et al. Repeated doses of UVR cause minor alteration in cytokine serum levels in humans. Mediators Inflamm 2005; 2005: 298-303.
21. Jacob SE, Nassiri M, Kerdel FA, et al. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 2003; 12: 309-13.
22. Abanmi A, Al Harthi F, Al Agla R, et al. Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia. Int J Dermatol 2005; 44: 82-3.
23. Bhushan M, McLaughlin B, Weiss JB, et al. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999; 141: 1054-60.
24. Guttman-Yassky E, Krueger JG,. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol 2007; 157: 1103-15.
25. Tammela T, Enholm B, Alitalo K, et al. The biology of vascular endothelial growth factors. Cardiovasc Res 2005; 65: 550-63.
26. Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2006; 126: 453-9.
27. Creamer D, Allen M, Jaggar R, et al. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002; 138: 791-6.
28. Nielsen HJ, Christensen IJ, Svendsen MN, et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 2002; 51: 563-7.
29. Nofal A, Al-Makhzangy I, Attwa E, et al. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. J Eur Acad Dermatol Venereol 2009; 23: 803-6.
30. Zhang Y, Matsuo H, Morita E,. Vascular endothelial growth factor 121 is the predominant isoform in psoriatic scales. Exp Dermatol 2005; 14: 758-64.
31. Simonetti O, Lucarini G, Goteri G, et al. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol 2006; 19: 751-60.
32. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
33. Naldi L, Gambini D,. The clinical spectrum of psoriasis. Clin Dermatol 2007; 25: 510-18.
34. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50: 859-66.
35. Sabat R, Sterry W, Philipp S, et al. Three decades of psoriasis research: where has it led us? Clin Dermatol 2007; 25: 504-9.
36. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-30.
37. Coimbra S, Oliveira H, Reis F, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci 2009; 55: 202-4.
38. Qiu S, Tan S, Zhang J, et al. Effect of liangxue huoxue xiaoyin tang on serum levels of TNF-alpha, IFN-gamma and IL-6 in psoriasis of blood-heat type. J Tradit Chin Med 2005; 25: 292-5.
39. Roussaki-Schulze AV, Kouskoukis C, Petinaki E, et al. Evaluation of cytokine serum levels in patients with plaque-type psoriasis. Int J Clin Pharmacol Res 2005; 25: 169-73.
40. Chodorowska G, Juszkiewicz-Borowiec M, Czelej D, et al. Activity of tumor necrosis factor-alfa (TNF-alpha) and selected acute phase proteins in plasma of psoriatic patients receiving local treatment. Ann Univ Mariae Curie Sklodowska [Med] 2001; 56: 165-9.
41. Akman A, Dicle O, Yilmaz F, et al. Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, re-PUVA and narrow-band UVB. Photodermatol Photoimmunol Photomed 2008; 24: 123-7.
42. Andrys C, Borska L, Pohl D, et al. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy. Arch Dermatol Res 2007; 298: 479-83.
43. McLoone P, Man I, Yule S, et al. Whole-body UVB (TL-01) or UVA-1 irradiation does not alter the levels of immunomodulatory cytokines in the serum of human volunteers. Photodermatol Photoimmunol Photomed 2004; 20: 76-80.
44. Sigmundsdottir H, Johnston A, Gudjonsson JE, et al. Narrowband-UVB irradiation decreases the production of pro-inflammatory cytokines by stimulated T cells. Arch Dermatol Res 2005; 297: 39-42.
45. Piskin G, Tursen U, Sylva-Steenland RM, et al. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers-IL-12, IL-18 and IL-23. Exp Dermatol 2004; 13: 764-72.
46. Krueger G, Ellis CN,. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53: S94-100.
47. Krueger JG, Bowcock A,. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64 (Suppl. 2): ii30-6.
48. Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 789-96.
49. McBride JD, Cooper MA,. A high sensitivity assay for the inflammatory marker C-reactive protein employing acoustic biosensing. J Nanobiotechnology 2008; 6: 5.
50. Di Cesare A, Di Meglio P, Nestle FO,. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129: 1339-50.
51. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122: 201-6.
52. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-90.
53. Farhi D,. Ustekinumab for the treatment of psoriasis. Drugs Today (Barc) 2010; 46: 259-64.
54. Zaba LC, SuÁrez-Fariías M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009; 124:1022-10.e1-395.
55. Karrer S, Eholzer C, Ackermann G, et al. Phototherapy of psoriasis: comparative experience of different phototherapeutic approaches. Dermatology 2001; 202: 108-15.
56. Yano K, Kadoya K, Kajiya K, et al. Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol 2005; 152: 115-21.
57. Guenther LC, Ortonne JP,. Pathophysiology of psoriasis: science behind therapy. J Cutan Med Surg 2002; 6: 2-7.